<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02210702</url>
  </required_header>
  <id_info>
    <org_study_id>14-06-FB-0118-HOSP</org_study_id>
    <nct_id>NCT02210702</nct_id>
  </id_info>
  <brief_title>Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales</brief_title>
  <official_title>Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Jones Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Jones Institute</source>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, controlled cohort study. This study will look at the&#xD;
      effect of Ethinyl Estradiol 35mcg/Norethindrone 1mg and Ethinyl Estradiol 20&#xD;
      mcg/Norethindrone 1mg on postpartum depressive symptoms and sexual function scores when&#xD;
      compared to a control group using no hormonal contraception. Depressive symptoms and sexual&#xD;
      function will be measured using the Edinburgh Postnatal Depression Scale (EPDS), Arizona&#xD;
      Sexual Experiences Scale (ASEX), and Brief Index of Sexual Functioning for Women (BISF-W).&#xD;
      Participants will begin taking the medication at Week 3 postpartum, and these outcomes will&#xD;
      be measured at baseline (0-1 day postpartum), Week 3, and Week 6-7. The investigators&#xD;
      hypothesize that there will be an ethinyl estradiol dose related response in EPDS, ASEX, and&#xD;
      BISF-W scores at Week 6-7, which would indicate a decrease in depressive symptoms and&#xD;
      increase in sexual function in both of the oral contraceptive groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Edinburgh Postnatal Depression Scale at baseline, 3 weeks postpartum and 6 weeks pospartum</measure>
    <time_frame>Baseline (0-1 days postpartum), Week 3 Postpartum, Week 6-7 Postpartum</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Arizona Sexual Experiences Scale scores at baseline, 3 weeks postpartum, and 6-7 weeks postpartum</measure>
    <time_frame>Baseline (0-1 days postpartum), Week 3 Postpartum, Week 6-7 Postpartum</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Brief Index of Sexual Functioning for Women scores at baseline, week 3 postpartum, and week 6-7 postpartum</measure>
    <time_frame>Baseline (0-1 days postpartum), Week 3 Postpartum, Week 6-7 Postpartum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Coitus</measure>
    <time_frame>Time to first coitus during postpartum period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Pregnancy Test</measure>
    <time_frame>Week 6-7 Postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Postpartum Depressive Mood</condition>
  <condition>Postpartum Sexual Function</condition>
  <arm_group>
    <arm_group_label>Ethinyl Estradiol 35mcg/Noethindrone 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21 day supply of Ethinyl Estradiol 35mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethinyl Estradiol 20mcg/Norethindrone 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21 day supply of Ethinyl Estradiol 20mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No hormonal contraception</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Women choosing copper IUD, spermicides, barrier methods, or sterilization (tubal ligation or partner vasectomy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinyl Estradiol 35mcg/Norethindrone 1mg</intervention_name>
    <arm_group_label>Ethinyl Estradiol 35mcg/Noethindrone 1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinyl Estradiol 20mcg/Norethindrone 1mg</intervention_name>
    <arm_group_label>Ethinyl Estradiol 20mcg/Norethindrone 1mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-45 year old women who desire contraception postpartum for at least 6 weeks.&#xD;
&#xD;
          -  18-45 year old women who choose not to use oral contraceptive medication postpartum&#xD;
             for at least 6 weeks for the control group.&#xD;
&#xD;
        Exclusion Criteria (Medication groups):&#xD;
&#xD;
          -  Breastfeeding (although this may limit participant enrollment, combined oral&#xD;
             contraceptives are contraindicated in this population).&#xD;
&#xD;
          -  Delivery by cesarean section.&#xD;
&#xD;
          -  Previous history of depression, mood disorders, or psychiatric disorders.&#xD;
&#xD;
          -  Any condition (history or presence of) which contraindicates the use of combination&#xD;
             OCs, including:&#xD;
&#xD;
          -  Thrombophlebitis or thromboembolic disorders, known or suspected clotting disorders,&#xD;
             deep vein thrombosis, thrombogenic valvulopathies or rhythm disorders.&#xD;
&#xD;
          -  Pulmonary Embolism.&#xD;
&#xD;
          -  Cerebrovascular or coronary artery disease or myocardial infarction.&#xD;
&#xD;
          -  Diabetes mellitus.&#xD;
&#xD;
          -  Migraine headaches with focal, neurological symptoms.&#xD;
&#xD;
          -  Chronic renal disease.&#xD;
&#xD;
          -  Uncontrolled or untreated hypertension.&#xD;
&#xD;
          -  Cholestatic jaundice.&#xD;
&#xD;
          -  Known or suspected carcinoma of the breast, endometrial carcinoma, or known or&#xD;
             suspected estrogen-dependent neoplasia.&#xD;
&#xD;
          -  Impaired liver function or disease, hepatic adenomas or carcinomas.&#xD;
&#xD;
          -  Known hypersensitivity to estrogens and/or progestins.&#xD;
&#xD;
          -  History of thyroid disorders.&#xD;
&#xD;
          -  Recent alcohol or drug use.&#xD;
&#xD;
          -  Smoking and age â‰¥35 or smokers who will become 35 years of age during the study.&#xD;
&#xD;
          -  Known history of noncompliance with taking medication.&#xD;
&#xD;
        Exclusion Criteria (Control group):&#xD;
&#xD;
          -  Previous history of depression, mood disorders, or psychiatric disorders.&#xD;
&#xD;
          -  Recent alcohol or drug use.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kelly McDaniel, MS</last_name>
    <email>mcdanik@evms.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>July 31, 2014</study_first_submitted>
  <study_first_submitted_qc>August 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2014</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression, Postpartum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone Acetate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

